Alexander Balck, MD

Clinician scientist

Name: Dr. med. Alexander Balck

Address: Institute of Neurogenetics, University of Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany

Phone: +49 451 3101 8221

Email: alexander.balck@neuro.uni-luebeck.de

Research fellow at the Institute of Neurogenetics, University of Lübeck

Resident at the Department of Neurology, University of Lübeck

Genetics of movement disorders with a focus Parkinson’s diseases;
Identification of novel drug candidates and biomarkers a subset of Parkinson’s disease (PD) patients with overt mitochondrial dysfunction (sysmedPD.eu).

Education:

2009 – 2015: Medical School (Lübeck and Göttingen)

2015 – 2016: Final year studies (Surgery: Montreal General Hospital, Mc Gill University, Canada; Internal Medicine: University of Galle, Sri Lanka; Neurology: University of Göttingen, Germany)

2011 – 2013: Medical Thesis (Laboratory of Paul Lingor, MD, Dept. of Neurology, Göttingen “Combination treatment with fasudil and riluzole in the SOD1-G93A mouse model of amyotrophic lateral sclerosis”

2016 – 2017: Research fellowship at the Institute of Neurogenetics, University of Lübeck, Germany

2017 – present: Medical residency at the Dept. of Neurology, University of Lübeck, Germany

2018 – 2019: Research fellowship at the Institute of Neurogenetics, University of Lübeck, Germany

Stipends:

2011 – 2016: Scholarship for Academic Excellence – ev. Studienwerk Villigst

2019 – present: Career development award in the context of a Clinician scientist program of the University of Lübeck (75.000€)

Reviewer Activities:

  • Annals of Neurology
  • Movement Disorders
  1. Dulovic-Mahlow M, Lukomska A, Diaw SH, Balck A, Borsche M, Grütz K, Lenz I, Rudolph F, Lohmann K, Klein C, Seibler P. Generation and characterization of human-derived iPSC lines from three pairs of monozygotic twins discordant for Parkinson’s disease. Stem Cell Res 2019:101629.
  2. Borsche M, Balck A, Kasten M, Lohmann K, Klein C, Brüggemann N. The sooner, the later – Delayed diagnosis in Parkinson’s disease due to Parkin mutations. Parkinsonism Relat Disord 2019:284-285.
  3. Balck A, Borsche M, Kasten M, Lohmann K, Seibler P, Brüggemann N, Klein C. Discordance in monozygotic Parkinson’s disease twins – continuum or dichotomy? Ann Clin Transl Neurol 2019;6:1102-1105.
  4. Westenberger A, Balck A, Klein C. Primary familial brain calcifications: genetic and clinical update. Curr Opin Neurol 2019;4:571-578.
  5. Trinh J, Lohmann K, Baumann H, Balck A, Borsche M, Brüggemann N, Dure L, Dean M, Volkmann J, Tunc S, Prasuhn J, Pawlack H, Imhoff S, Lill CM, Kasten M, Bauer P, Rolfs A, International Parkinson’s Disease Genomics Consortium (IPDGC)., Klein C. Utility and implications of exome sequencing in early-onset Parkinson’s disease. Mov Disord 2018;1:133-137.
  6. Dulovic M, Schäffer E, Leypoldt F, Balck A, Schaake S, Hinrichs F, Kirchner H, Brüggemann N, Berg D, Lohmann K. A Klinefelter patient with an additional mitochondrial mutation: Implications for genotype-driven treatment and mitochondrial mutational load in different tissues and family members. Parkinsonism Relat Disord 2018:116-118.
  7. Kasten M, Hartmann C, Hampf J, Schaake S, Westenberger A, Vollstedt EJ, Balck A, Domingo A, Vulinovic F, Dulovic M, Zorn I, Madoev H, Zehnle H, Lembeck CM, Schawe L, Reginold J, Huang J, König IR, Bertram L, Marras C, Lohmann K, Lill CM, Klein C. Genotype-Phenotype Relations for the Parkinson’s Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review. Mov Disord 2018;5:730-741.
  8. Balck A, Hanssen H, Hellenbroich Y, Lohmann K, Münchau A. Adult-onset ataxia or developmental disorder with seizures: two sides of missense changes in CACNA1A. J Neurol 2017;7:1520-1522.
  9. Balck A, Klein C. Reduced penetrance of Leucine-rich repeat kinase 2 mutations: Discovering genetic factors of endogenous disease protection. Mov Disord 2017;4:527.